HCPCS Code A4642: Satumomab pendetide billing and Medicare coverage guide

Key Takeaways

HCPCS Code A4642 is not a generic radiolabeled-antibody bucket code. Its official CMS descriptor is “Indium In-111 satumomab pendetide, diagnostic, per study dose, up to 6 millicuries” – a single, specific named agent

Satumomab pendetide, marketed as OncoScint CR/OV, was withdrawn from the US market in December 2002, and Cytogen Corporation halted further development in 2006 – so A4642 is now effectively a legacy code, not one tied to active cancer imaging

Medicare Part B coverage still depends on medical necessity documentation and the applicable Local Coverage Determination (LCD), even though contemporary claims for this specific agent are rare

Practice management software like Pabau helps oncology and imaging practices track legacy HCPCS supply codes, attach supporting documentation, and avoid miscoding a currently marketed radiolabeled antibody under a discontinued agent’s code

HCPCS Code A4642 reports Indium In-111 satumomab pendetide, diagnostic, per study dose, up to 6 millicuries. The agent was marketed as OncoScint CR/OV, an Indium-111-labeled monoclonal antibody once used to stage colorectal and ovarian cancer. The code names that single product rather than serving as a generic radiolabeled-antibody placeholder.

OncoScint CR/OV was withdrawn from the US market in December 2002. Manufacturer Cytogen Corporation halted further development in 2006, after PET imaging showed comparable or better tumor detection.

The code remains on the HCPCS Level II list, but billing A4642 in 2026 typically means resolving a legacy claim, correcting historical records, or confirming that a different, currently marketed agent hasn’t been miscoded under it.

HCPCS Code A4642: Official description and classification

HCPCS Code A4642 is a Level II supply code with a single official descriptor: “Indium In-111 satumomab pendetide, diagnostic, per study dose, up to 6 millicuries.” The Centers for Medicare & Medicaid Services (CMS), which maintains the HCPCS Level II code set, classifies A4642 within the A-series of codes designated for medical and surgical supplies.

Unlike many A-series entries that describe a category of supply, A4642 names one specific agent: satumomab pendetide, marketed under the brand name OncoScint CR/OV, a murine monoclonal antibody labeled with Indium-111 that targets the TAG-72 tumor-associated antigen found in many adenocarcinomas.

Practices using claims management tools should store the full official descriptor alongside the code, since an abbreviated or informal description (such as “radiolabeled antibody”) can lead a coder to apply A4642 to a completely different, currently marketed agent by mistake.

Because A4642 names one specific, discontinued agent rather than a category, coders should not treat it as a fallback for any radiolabeled antibody supply. If a patient is receiving a currently marketed radiolabeled antibody imaging agent, that product will have its own specific HCPCS or CPT code, and A4642 does not apply.

Where A4642 does appear on a current claim, it is most often tied to a legacy patient record, a retrospective audit, or a correction to a historical claim rather than a new administration.

Medicare coverage for A4642

Medicare Part B may cover A4642 when the service is considered medically necessary and the treating physician has documented a qualifying clinical indication. Coverage is not automatic. The applicable Medicare Administrative Contractor (MAC) jurisdiction determines specific coverage criteria through a Local Coverage Determination (LCD).

Practices billing across multiple MAC regions should verify the relevant LCD before submitting claims, because coverage rules can vary by jurisdiction, even for a code with limited contemporary use.

Key coverage considerations for A4642 under Medicare Part B include the following:

• The record must confirm the agent administered was Indium In-111 satumomab pendetide specifically, with a documented clinical rationale in the patient chart
• The ordering provider must be enrolled in Medicare and have a valid National Provider Identifier (NPI)
• The imaging study must address a covered diagnosis; historically, oncology indications (colorectal or ovarian cancer staging, restaging, or treatment response evaluation) were the qualifying scenarios for this agent
• The supply must not be separately reimbursable if it is already included in the Outpatient Prospective Payment System (OPPS) bundled payment for the associated imaging procedure
• The claim must be submitted on the CMS-1500 form (or electronic equivalent) with the correct place of service code and supporting ICD-10-CM diagnosis codes

Where no National Coverage Determination (NCD) applies directly to A4642, the MAC’s LCD governs. Confirm the applicable LCD through your MAC’s published policy documents before billing. Teams using EHR integration for billing workflows can automate this documentation cross-check at the point of claim creation.

Reimbursement rates and payment policy

CMS sets reimbursement rates for HCPCS Level II supply codes through the Medicare Physician Fee Schedule (MPFS) and, in hospital outpatient settings, through OPPS. For A4642, the applicable payment methodology depends on the place of service where the agent is administered, though in practice the volume of active claims for this specific, discontinued agent is low.

Because MPFS rates are updated annually, billers should verify the current payment amount each January using the CMS Physician Fee Schedule search tool, even for a low-volume legacy code like A4642.

Relying on prior-year rates is a common cause of underbilling. Practices with strong medical forms and administrative workflows can build annual rate-review reminders into their billing calendar to catch these changes.

How to bill HCPCS Code A4642

Accurate claim submission for HCPCS Code A4642 requires correct field population on the CMS-1500 form and careful pairing with the procedure and diagnosis codes that establish medical necessity. Because the code names a single, discontinued agent, the first step is confirming that A4642 is even the right code for what was administered.

The steps below reflect standard Medicare billing practice; commercial payer requirements may differ.

1. Confirm the agent administered. Verify in the patient record that the agent was specifically Indium In-111 satumomab pendetide (OncoScint CR/OV). If a different radiolabeled antibody was used, A4642 is the wrong code – look up that agent’s own specific HCPCS or CPT code instead.
2. Confirm separate billability. Verify that A4642 is not bundled into the payment for the associated nuclear medicine or imaging procedure code. Bundling edits under OPPS can make separate billing inappropriate in hospital outpatient settings.
3. Select the correct procedure code. Pair A4642 with the appropriate nuclear medicine imaging CPT code (such as an immunoscintigraphy or antibody imaging study code) that reflects the specific service performed.
4. Assign supporting ICD-10-CM codes. Append the diagnosis codes that establish medical necessity, typically an oncology or disease-staging code. Confirm these align with the applicable LCD coverage criteria.
5. Populate the ordering provider fields. Enter the ordering physician’s name, NPI, and address in the correct CMS-1500 fields. Missing or incorrect ordering provider data is a leading denial trigger.
6. Enter the place of service code. Use the correct Place of Service (POS) code to reflect where the agent was administered. This determines which payment system applies.
7. Attach supporting documentation. Ensure the patient’s medical record, physician order, and any required prior authorization confirmation are retrievable for post-payment audit or appeal.

Teams using patient data security tools can store claim-supporting documentation alongside the patient record, reducing retrieval time during audits. Medical practice management software with integrated billing workflows also makes it easier to flag incomplete claims before submission.

Applicable modifiers

Certain modifiers may be appended to A4642 depending on the clinical and administrative circumstances. Modifier applicability should always be verified against current CMS claims processing instructions and the relevant MAC’s guidance, as modifier rules can change with annual updates.

Verify each modifier’s applicability with your MAC before appending it. Incorrect modifier usage can trigger claim denials or improper payment adjustments that require costly appeals. Using compliance management tools helps billing teams track modifier rules and flag discrepancies before claims leave the practice.

Reduce HCPCS billing errors before they become denials

Pabau helps oncology and imaging practices track supply codes (including older, single-agent codes like A4642), attach supporting documentation to patient records, and manage compliance workflows, so your team spends less time on claim appeals and more time on patient care.

Book a demo

Documentation requirements for billing A4642

Insufficient documentation is the single most common reason A4642 claims fail post-payment audit. Because the code names one specific, discontinued agent, auditors also look for confirmation that the agent administered was in fact Indium In-111 satumomab pendetide, rather than a different radiolabeled antibody billed under the wrong code. The following documentation should be present in the patient record at the time of billing.

• Physician order: a signed, dated order from the treating or ordering physician specifically naming Indium In-111 satumomab pendetide (OncoScint CR/OV)
• Clinical notes establishing medical necessity: progress notes, consultation reports, or diagnostic workup results that justify the imaging study and confirm which agent was used
• ICD-10-CM diagnosis documentation: the medical record must support each diagnosis code submitted on the claim
• Imaging study report: the nuclear medicine or radiology report confirming the study was performed and the specific agent was used
• Advance Beneficiary Notice (ABN): if medical necessity is uncertain, an ABN must be issued to the patient before service delivery and retained in the file
• Prior authorization confirmation: where the payer requires prior auth, retain the approval reference number and expiration date

Practices that implement digital documentation tools can standardize the collection of these elements at the point of care, reducing the back-office burden of chasing records during an audit.

HIPAA-compliant documentation practices also ensure that the retained records are stored and accessed securely, which is a separate but related audit risk.

Teams looking at broader practice management platforms should confirm that the chosen system supports document attachment at the claim or encounter level.

Related HCPCS codes

A4642 is easy to confuse with codes that look similar on paper but work very differently. The table below compares A4642 with related HCPCS codes billers may encounter in the same claim context, and clarifies which ones are genuine catch-all codes versus specific, single-agent codes like A4642 itself.

The rule when selecting among radiolabeled imaging codes is confirmation, not a fallback hierarchy. A4642 applies only when the agent administered is Indium In-111 satumomab pendetide. If a different named agent was used, its own A9-series or Q-series code applies instead.

The same specificity rule runs across HCPCS Level II more broadly: A-series supply codes like A4629 and J-series drug codes like J1442 each name one product, so using the wrong one carries the same denial risk as misusing A4642.

The AAPC Codify HCPCS code search and the PGM Billing HCPCS lookup tool both allow keyword searches across the full HCPCS Level II code set, helping coders confirm the agent-specific code that matches what was actually administered. Practices using lab and imaging workflow management software can cross-reference administered agents against their code library at the point of documentation.

Common billing errors and how to avoid them

A4642 claims carry a higher-than-average denial risk because the code names a single, discontinued agent that billers can easily misapply to a different, currently marketed product. These are the errors billing teams encounter most often, along with practical fixes for each.

• Billing A4642 for a different radiolabeled antibody agent. Because A4642 is specific to Indium In-111 satumomab pendetide, using it as a generic stand-in for any radiolabeled antibody will misidentify the supply and likely trigger a denial or an audit finding. Fix: Confirm the exact agent name in the physician order and imaging report before selecting a code, and look up that agent’s own HCPCS or CPT code if it isn’t satumomab pendetide.
• Billing A4642 separately in an OPPS setting. In hospital outpatient departments, the supply cost is frequently packaged into the APC payment for the associated imaging procedure. A separate A4642 claim on the same date of service for the same patient will be denied as a duplicate or bundled item. Fix: Confirm the applicable APC packaging status before submitting the supply code as a separate line item.
• Missing or mismatched ordering provider information. CMS-1500 fields 17 and 17a require the ordering/referring provider’s name and NPI. Errors here generate automatic edits that delay or deny payment. Fix: Validate ordering provider NPI against the Medicare provider enrollment records before claim submission.
• Unsupported diagnosis codes. If the ICD-10-CM codes on the claim do not align with the conditions listed in the applicable LCD, the claim will be denied for medical necessity. Fix: Build a crosswalk between common oncology diagnosis codes and the MAC’s LCD coverage criteria, and review it each time the LCD is updated.
• Failing to append the KX modifier when required. Some MACs require the KX modifier as a condition of payment to confirm that LCD documentation criteria have been met. Omitting it results in an automatic denial. Fix: Identify which MACs in your billing jurisdiction require KX for A4642 and add it to the billing workflow as a standing rule.

Teams that use integrated practice management software can build pre-submission claim edits for each of these error types, catching problems before the claim reaches the payer rather than after a denial. This discipline matters across specialties, from GP clinic software environments handling routine Medicare billing to IV therapy practices administering infused or injected agents. The time saved on rework typically exceeds the time invested in configuring the checks.

Conclusion

HCPCS Code A4642 names one specific, discontinued agent – Indium In-111 satumomab pendetide, marketed as OncoScint CR/OV – not a generic radiolabeled-antibody bucket. Confirming the agent actually administered, verifying LCD criteria by MAC jurisdiction, and populating all CMS-1500 ordering provider fields before submission resolves the majority of denial patterns for this now-legacy code.

Pabau’s claims management tools help imaging and oncology practices attach supporting documentation to patient records, track HCPCS supply codes (including older, single-agent codes like A4642), and build pre-submission validation into their billing workflows. To see how Pabau handles the administrative side of complex supply code billing, book a demo.

Continue your research

Working with another single-agent DME code? HCPCS Code K0108 covers wheelchair components billed as not-otherwise-specified items, with the same specificity requirements as A4642.

Billing a home care service code? HCPCS Code S5130 explains how homemaker services are billed per 15-minute increments.

Need an anesthesia code reference? CPT Code 00103 covers anesthesia for eyelid procedures, another narrowly defined billing code.

Frequently asked questions